Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Article excerpt
Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional PARSIPPANY, N.J.--(BUSINESS WIRE)-- $ZTS #animalhealth -- Zoetis Inc. (NYSE: ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Convenia® RTU for Dogs (cefovecin injectable suspension) for the treatment of susceptible bacterial skin infections in dogs. For many families, administering oral antibiotics daily for one to two weeks can be difficult, especially when a dog resists medication or a household schedule makes routine timing hard to maintain. Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections in dogs and is administered by a veterinary health professional, supporting complete dose compliance. “Anyone who has tried to give a dog pills for a week or two knows how challenging it can be to stay on schedule. Convenia® (cefovecin sodium) has been a veterinarian-trusted treatment for susceptible bacterial skin infections for over a decade and has helped remove the burden of continued and accurate dosing that is typically required with oral antibiotics,” said Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis. “With Convenia RTU for Dogs, we are building on the...
Keep reading with a free account
The rest of this article, and every signal for Zoetis, is in your free account.
Extracted from this sentence
Convenia RTU for Dogs is expected to be available to veterinarians in Q1 2027 as part of Zoetis’ expanding portfolio of products designed to broaden treatment options for all dogs, especially medium to large breeds.
